Meta-analysis · people

Abaloparatide: larger hip BMD gains than teriparatide at 24 weeks

Checked against the paper Meta-analysisPublished by PepVault

The takeaway

In pooled trials of postmenopausal women, abaloparatide gave somewhat larger hip bone density gains than teriparatide with less hypercalcemia, but whether that means fewer fractures was not settled.

Kind
Meta-analysis
Studied in
People
Published
2023
Journal
J Orthop Surg Res

What they tested

The team asked whether abaloparatide raises bone mineral density more than teriparatide in postmenopausal women with osteoporosis, and how the two compare on side effects.

How the study was done

A meta-analysis, which pools results from several studies, covering 16 subgroups of postmenopausal women with osteoporosis. It drew on randomized controlled trials and post hoc analyses of them, published up to September 2, 2022, and compared abaloparatide with teriparatide and with placebo, a dummy treatment.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking abaloparatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At 24 weeks, every bone mineral density (BMD) measure except the lumbar spine favored abaloparatide over teriparatide. Only the femoral neck and total hip results reached high quality on the GRADE scale, a rating of how trustworthy the evidence is: weighted mean difference 1.58 [0.52, 2.63] at the femoral neck and 1.46 [0.59, 2.32] at the total hip. Serious side effects and deaths showed no clear difference between the drugs, and hypercalcemia, too much calcium in the blood, was 51% less common with abaloparatide than with teriparatide. Compared with placebo, abaloparatide carried higher risks of nausea and palpitations.

What it doesn’t show

The pool of studies was small, and every head-to-head trial was sponsored by the manufacturer. The fracture data were too limited to judge whether either drug prevents more fractures.

The paper

Hong et al. Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis. J Orthop Surg Res. 2023.

The compounds

More studies on Abaloparatide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking abaloparatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo